Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

This publication has 22 references indexed in Scilit:

• Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
  Journal of Thrombosis and Haemostasis, 2008
• Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
  Journal of Thrombosis and Haemostasis, 2008
• The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
  Journal of Thrombosis and Haemostasis, 2007
• Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
  Journal of Medicinal Chemistry, 2007
• Bleeding Complications With Warfarin Use
  Archives of internal medicine (1960), 2007
• Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits
  Journal of Cardiovascular Pharmacology, 2007
• Low-Dose Aspirin for the Prevention of Atherothrombosis
  New England Journal of Medicine, 2005
• Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients
  European Heart Journal, 2005
• Clopidogrel and Ticlopidine: P2Y₁₂Adenosine Diphosphate-Receptor Antagonists for the Prevention of Atherothrombosis
  Seminars in Thrombosis and Hemostasis, 2005
• Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
  New England Journal of Medicine, 2001